1.39 0.01 (0.72%) | 02-18 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 1.64 | 1-year : | 1.92 |
Resists | First : | 1.4 | Second : | 1.64 |
Pivot price | 1.31 ![]() |
|||
Supports | First : | 1.21 | Second : | 1.09 |
MAs | MA(5) : | 1.38 | MA(20) : | 1.27 ![]() |
MA(100) : | 1.09 ![]() |
MA(250) : | 0.98 ![]() |
|
MACD | MACD : | 0 ![]() |
Signal : | 0 ![]() |
%K %D | K(14,3) : | 92.5 ![]() |
D(3) : | 91.8 ![]() |
RSI | RSI(14): 75.5 ![]() |
|||
52-week | High : | 1.75 | Low : | 0.62 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ACHL ] has closed below upper band by 33.4%. Bollinger Bands are 144.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 1.39 - 1.4 | 1.4 - 1.4 |
Low: | 1.36 - 1.37 | 1.37 - 1.38 |
Close: | 1.38 - 1.39 | 1.39 - 1.4 |
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Sun, 16 Feb 2025
Achilles Therapeutics plc (NASDAQ:ACHL) Short Interest Down 52.8% in January - MarketBeat
Tue, 04 Feb 2025
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Tue, 04 Feb 2025
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Tue, 24 Dec 2024
Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca - GlobeNewswire
Tue, 24 Dec 2024
Achilles Therapeutics sells technology assets to AstraZeneca - Seeking Alpha
Tue, 19 Nov 2024
Achilles Therapeutics Gets 180-Day Extension After Nasdaq Market Transfer - StockTitan
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 41 (M) |
Shares Float | 21 (M) |
Held by Insiders | 6.5 (%) |
Held by Institutions | 86 (%) |
Shares Short | 58 (K) |
Shares Short P.Month | 122 (K) |
EPS | -1.66 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 2.5 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -30.2 % |
Return on Equity (ttm) | -52.2 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -1.64 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -63 (M) |
Levered Free Cash Flow | -45 (M) |
PE Ratio | -0.84 |
PEG Ratio | 0 |
Price to Book value | 0.55 |
Price to Sales | 0 |
Price to Cash Flow | -0.91 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |